Poly-D Tech

The company develops and produces high-performance fluorescent nanoparticles with unique characteristics to improve the detection of biomarkers in the service of scientific research and medical diagnosis, offering higher detection sensitivity with user-friendly protocols applicable to various   molecular and cellular biology techniques. The technology is the result of more than ten years of research and collaboration between experts in nanoparticle synthesis, spectroscopy, medical imaging, and IVD techniques from France and Hong Kong. This synergy has made it possible to create state-of-the-art lanthanide-based fluorescent nanoparticles with unparalleled performance. Their unique characteristics allow results that far exceed any existing products, improving the detection of all types of biomarkers in various types of samples and concentration levels, including undetected biomarkers, creating a whole new world of possibilities in the healthcare and life sciences.

Website : https://poly-dtech.com

To find out more about Ploy-D tech products and services, click here

 

 
SARS-CoV-2 - Antibodies for research and development

SARS-CoV-2 - Antibodies for research and development

 

The ongoing COVID-19 pandemic has sickened over 520,000 people worldwide. There is an urgent need to increase the current diagnosis capacity. Compared with the commonly-used PCR testing, serological assay-based diagnostic method is much easier and faster to perform. To support the development of immunodiagnostic methods, we offer a complete collection of antibodies and antigens for SARS-CoV-2.
 
We other both primary and secondary antibodies for detection and diagnostic tools development :
  • Primary antibodies against the 2 main protein of SARS-CoV-2 : Nucleocapsid protein (N protein) and Spike protein (S protein) 
  • Secondary antibodies against human IgG and IgM antibodies in order to detect the anti-SARS-CoV-2 in patient samples
These antibodies can be used to quantify antigens on the surface of SARS-CoV-2 (or antigens expressed recombinantly) or anti-SARS-CoV-2 antibodies in patient samples.